Sunday July 21, 2019
Home India Spicy lies: Y...

Spicy lies: Yippee ad claims being safe, FDA disagrees

0
//

img1440393117822By NewsGram Staff Writer

After the recent Maggi ban and its subsequent upliftment, now Yippee noodles is on the path of courting controversy.

Today’s  Hindustan Times flashed a huge brightly colored advertisement that claims that Yipee is safe and bases the claim on a number of tests it underwent to prove its credibility. However, Indian Express, dated 24th August 2015, in a report claims that excessive lead has been found in the samples of Yippee noodles.

The report says that Uttar Pradesh Food and Drug Authority (FDA) recently found excess lead in ITC’s Yippee noodles. The samples tested contained lead amount  “in excess to the permissible limit”. The tested samples had 1.057 ppm of lead as against the permissible amount of below 1 ppm.

The report has been sent to the FDA Chief Commissioner for permission before filing an official case.

 

 

 

 

Next Story

FDA Warns Patients about Cybersecurity Concerns with Certain Medtronic Insulin Pumps

Patients with diabetes using the affected models should switch their insulin pump to models that are better equipped

0
ransomware
The ransomware takes advantage of the architecture of the central processing unit (CPU) to avoid detection - functionality that is not often seen in ransomware. Pixabay

With the US Food and Drug Administration (FDA) issuing a warning to health care providers this week that certain Medtronic insulin pumps have potential cybersecurity risks, the company said no patient issues have been reported in India so far.

While the US FDA said that Medtronic was recalling several affected MiniMed pumps and providing alternative insulin pumps to patients, insulin pumps are not being recalled in India.

Patients with diabetes using the affected models should switch their insulin pump to models that are better equipped to protect against these potential risks, the FDA said.

Medtronic India said it has started notifying customers of a potential cybersecurity risk in the MiniMed 508 and MiniMed Paradigm series of insulin pumps. These models are from 2012 and earlier.

US, FDA, Cybersecurity
With the US Food and Drug Administration (FDA) issuing a warning to health care providers this week that certain Medtronic insulin pumps have potential cybersecurity risks. Pixabay

“An unauthorised person with special technical skills and equipment could potentially connect wirelessly to a nearby insulin pump to change settings and control insulin delivery. At this time, we have not received any confirmed reports of unauthorized persons changing settings or controlling insulin delivery,” Medtronic India said in a statement.

“Kindly note that the insulin pumps are not being recalled and are not required to be returned. This is a safety notification only,” it added.

MiniMed 508 had been discontinued in India since 2011.

Also Read- Central Government to Launch ‘One Nation, One Ration Card’ Scheme in a Bid to Curb Corruption

“In India, Medtronic is proactively informing the regulators and other relevant stakeholders and is in the process of working with researchers, doctors and patients to address any questions or concerns that they may have,” the US-based medical device manufacturer said. (IANS)